

TALi Appoints Former Cochlear Executive as Interim Chief Executive Officer in addition to role as Chief Medical Officer

TALi Digital Ltd (ASX: TD1, "TALi" or "the Company") is pleased to advise of the appointment of Dr Mary Elizabeth Brinson as Interim Chief Executive Officer in addition to her role as Chief Medical Officer. Dr Brinson was former Vice President, Global Clinical Affairs, with medical devices leader Cochlear Limited (ASX: COH).

Mary Beth holds a Doctorate in Audiology from the University of Louisville in Kentucky, a Master of Business Administration from Rutgers University in New Jersey and a bachelor's degree in Audiology and Speech Pathology from the University of Georgia in the United States.

Mary Beth has held a number of senior roles during a 16-year career at Cochlear including Director of Quality, Clinical and Regulatory Services and Director of Clinical Services, Research and Professional Training. She is a qualified Audiologist and has practiced in healthcare and academia in the U.S. and United Kingdom. She is also an Adjunct Fellow at Macquarie University in Sydney.

"We're thrilled that Mary Beth has agreed to step up to the role on Interim Chief Executive Officer in addition to her role as Chief Medical Officer," said TALi Chair Sue MacLeman. "The Board and Executive have been working on a full operational review of the business and Mary Beth's background and leadership provides an excellent foundation for supporting the TALi corporate mission to bring the benefits of strong attention to young children. Her experience leading teams at Cochlear, one of the world's most successful medical devices businesses, will be invaluable as we work to make the benefits of TALi's innovative digital therapeutic available to patients."

Her appointment in this new combined role takes effect 27th April 2022. The remuneration details are outlined below.

Terms and conditions of Dr Brinson appointment as Interim CEO

- Appointment effective immediately
- Total remuneration package of \$310,000 per annum (base salary) exclusive of superannuation
- Short term incentive (STI) - eligible for a bonus up to 35% of base salary payable at the Boards discretion upon achievements of mutually agreed key performance indicators (KPI's)
- Long Term incentive (LTI) - eligible for the shareholder approved Employee Share Option Plan (ESOP)
- Both Dr Brinson and the Company are required to provide four weeks notice of resignation or termination respectively

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Corporate

Sue MacLeman
TALi Digital Chair
1300 082 013
investors@talidigital.com

About TALi Digital

TALi Digital Limited (ASX: TD1) is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy, placing TALi at the forefront of improving early intervention for childhood attention and concentration performance. We believe in healthy, happier minds – our vision is to deliver a personalised digital experience to enhance cognitive care.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Learn more at talidigital.com.